Company / SG&A Expense
Haemonetics SG&A Expense History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$429.8M
FY2026
5-year range
$376.7M / $436.8M
FY2022-FY2026
Trend
-
vs FY2025
Sector context
#75 of 158
Health Care
What the data says
At $430M, Haemonetics's sg&a expense ranks #84 of 158 in the Health Care sector. SG&A Expense has fluctuated over the past 9 years, ranging from $273M in FY2018 to $437M in FY2024.
Based on SEC 10-K filings.
$430M in FY2026 with a 5-year CAGR of +4.8%.
Remained stable around $430M over the past 3 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -0.2%
- 5-Year CAGR
- +4.8%
- 10-Year CAGR
- -
Sector benchmark
#84 of 158 in Health CareTop 53% of 158This company $429.8M Sector average $175.9B
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.8%, indicating consistent growth.
- Ranks #75 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
- Lowest sg&a expense in the period was in FY2018.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $429.8M | - |
| FY2025 | - | - |
| FY2024 | $436.8M | +1.2% |
| FY2023 | $431.8M | +14.6% |
| FY2022 | $376.7M | +10.7% |
| FY2021 | $340.1M | +23.6% |
| FY2020 | $275.2M | -2.4% |
| FY2019 | $282.0M | +3.1% |
| FY2018 | $273.5M | -13.6% |
| FY2017 | $316.5M | +4.9% |
As of FY2026 · SEC 10-K · Updated Jun 30, 2026